Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Thematic (Sector/Industry)

If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the Korea IPO market shined in the first half of 2016.  <ul>
<li>The 19 stocks that we have tracked that have completed their IPOs in the Korean Stock Exchange in 1H 2016 are up on average 35% (from IPO offer price to closing price as of 4 July 2016). </li>
<li>Some of the best performers include Qurient Co., <a href="https://www.smartkarma.com/entities/22709" target="_blank" data-smartkarma-citation="entities:22709">Haitai Confectionery &amp; Foods</a> (see <a href="https://www.smartkarma.com/insights/haitai-confectionery-ipo-preview" target="_blank" data-smartkarma-citation="insights:3494">Haitai Confectionery - IPO</a>…</li>
</ul>

If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the Korea IPO market shined in the first half of 2016.  
The 19 stocks that we have tracked that have completed their IPOs in the Korean Stock Exchange in 1H 2016 are up on average 35% (from IPO offer price to closing price as of 4 July 2016). 
Some of the best performers include Qurient Co., Haitai Confectionery &amp; Foods (see Haitai Confectionery - IPO…


What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....

In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this Part II of our report, we dug deeper and identified 17 more companies that planning to complete IPOs in Korea in 2016. We believe that IPOs of these 36 companies are likely to represent more than 90% of all capital raised through IPOs this year in the Korea Stock Markets.Of these 36 companies planning to complete IPOs, consumer discretionary sector…

In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this Part II of our report, we dug deeper and identified 17 more companies that planning to complete IPOs in Korea in 2016. We believe that IPOs of these 36 companies are likely to represent more than 90% of all capital raised through IPOs this year in the Korea Stock Markets.Of these 36 companies planning to complete IPOs, consumer discretionary sector…

2016 Major IPOs Pipeline in Korea - Part II

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in 2008. In this report, we highlight some of the major IPOs that are in the pipeline for 2016. Recapping 2015, there were 128 companies in Korea that completed IPOs (including 19 new listings in KOSPI and 109 new listings in KOSDAQ markets). The IPO market in Korea is off to a solid start. JS Corporation (194370KS), a leading ODM (original design…

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in 2008. In this report, we highlight some of the major IPOs that are in the pipeline for 2016. Recapping 2015, there were 128 companies in Korea that completed IPOs (including 19 new listings in KOSPI and 109 new listings in KOSDAQ markets). The IPO market in Korea is off to a solid start. JS Corporation (194370KS), a leading ODM (original design…

Global Healthcare Analyst

Tina Banerjee

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals (326030 KS)</a> (SKBP) has announced that <a href="https://www.smartkarma.com/entities/sk-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:393:1" rel="noopener">SK Inc (034730 KS)</a> plans to offload ~11M shares of SKBP on March 30, 2026 at a price of KRW114,500 per share.</li>
<li>Although SK Inc is reducing its stake ~14% in SKBP, it will remain the majority shareholder, thereby retaining the control and management rights in the company.</li>
<li>SK Inc’s stake sale should not impact future growth prospect of SKBP, as the company has multiple growth drivers. FDA-approved epilepsy drug Xcopri is the main and near-term growth engine.</li>
</ul>



SK Biopharmaceuticals (326030 KS) (SKBP) has announced that SK Inc (034730 KS) plans to offload ~11M shares of SKBP on March 30, 2026 at a price of KRW114,500 per share.
Although SK Inc is reducing its stake ~14% in SKBP, it will remain the majority shareholder, thereby retaining the control and management rights in the company.
SK Inc’s stake sale should not impact future growth prospect of SKBP, as the company has multiple growth drivers. FDA-approved epilepsy drug Xcopri is the main and near-term growth engine.


SK Biopharmaceuticals (326030 KS): Parent’s Stake Sale Does Not Tarnish Future Growth Prospect

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> reported strong 4Q25 result, with all key parameters showing improvement on sequential as well as YoY basis, driven by strong sales of prescription drug business.</li>
<li>HK inno’s U.S. partner has submitted a New Drug Application (NDA) to the FDA for K-CAB. The company expects to launch K-CAB in the U.S. by January next year.</li>
<li>Going ahead, HK inno is expected to maintain growth momentum, mainly riding on the back of prescription drug business, especially K-CAB. Bottomline is expected to widely outperform revenue growth.</li>
</ul>



HK inno.N (195940 KS) reported strong 4Q25 result, with all key parameters showing improvement on sequential as well as YoY basis, driven by strong sales of prescription drug business.
HK inno’s U.S. partner has submitted a New Drug Application (NDA) to the FDA for K-CAB. The company expects to launch K-CAB in the U.S. by January next year.
Going ahead, HK inno is expected to maintain growth momentum, mainly riding on the back of prescription drug business, especially K-CAB. Bottomline is expected to widely outperform revenue growth.


HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card

South Korea

Hanmi Pharm. Company Ltd. produces pharmaceutical products, including antibiotics, vitamins, and intestinal tonics.  The Company also provides beverages and processes soft capsules for other pharmaceutical firms.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hanmi Pharm (128940 KS)

What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....

If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...

Douglas Kim

2016 Major IPOs Pipeline in Korea - Part II

In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...

Douglas Kim

2016 Major IPOs Pipeline in Korea

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in...

Douglas Kim

SK Biopharmaceuticals (326030 KS): Parent’s Stake Sale Does Not Tarnish Future Growth Prospect

SK Inc plans to offload shares of SK Biopharmaceuticals, but will remain majority shareholder. SKBP has multiple growth drivers, with FDA-approved...

Tina Banerjee

HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card

HK inno.N reports strong 4Q25 results, driven by prescription drug sales. The company has filed NDA for K-CAB in the U.S. and expects to launch...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....

If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...

Douglas Kim

2016 Major IPOs Pipeline in Korea - Part II

In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...

Douglas Kim

2016 Major IPOs Pipeline in Korea

This year appears to be an exciting year for IPOs in Korea, barring a dramatic downturn in global equities markets like the one we experienced in...

Douglas Kim

SK Biopharmaceuticals (326030 KS): Parent’s Stake Sale Does Not Tarnish Future Growth Prospect

​SK Inc plans to offload shares of SK Biopharmaceuticals, but will remain majority shareholder. SKBP has multiple growth drivers, with FDA-approved...

Tina Banerjee

HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card

​HK inno.N reports strong 4Q25 results, driven by prescription drug sales. The company has filed NDA for K-CAB in the U.S. and expects to launch...

Tina Banerjee

SK Inc plans to offload shares of SK Biopharmaceuticals, but will remain majority shareholder. SKBP has multiple growth drivers, with FDA-approved...

HK inno.N reports strong 4Q25 results, driven by prescription drug sales. The company has filed NDA for K-CAB in the U.S. and expects to launch...